Genmab

Genmab is an international biotechnology company specializing in the discovery and development of antibody therapeutics for cancer and other serious diseases. Founded in 1999, Genmab has become one of Europe’s most successful biotech firms, known for its expertise in antibody engineering and its innovative oncology pipeline.

Mission and Vision

Mission: To improve the lives of patients by creating and developing differentiated antibody therapeutics.
Vision: To transform cancer treatment and become a fully integrated biotech company delivering proprietary medicines to patients worldwide.

Products and Services

Marketed Antibody Medicines (in partnership):
- Darzalex (daratumumab, with Janssen) – for multiple myeloma.
- Kesimpta (ofatumumab, with Novartis) – for multiple sclerosis.
- Tivdak (tisotumab vedotin, with Seagen) – for cervical cancer.
Pipeline Programs: Broad oncology-focused pipeline including bispecific antibodies and next-generation antibody-drug conjugates (ADCs).
Technology Platforms: Proprietary antibody technologies such as DuoBody® (bispecifics), HexaBody®, and HexElect®.

Growth and Innovation
Genmab established itself as a leader in antibody science with the success of Darzalex, one of the most widely used therapies for multiple myeloma. The company continues to expand its proprietary pipeline and collaborations with global pharma leaders like Janssen, Novartis, AbbVie, and BioNTech. Genmab aims to transition into a fully integrated biopharma company, moving beyond licensing into commercializing its own medicines.

Global Impact
With offices and research centers across Europe, the U.S., and Japan, Genmab’s therapies are improving outcomes for patients worldwide. Its antibody platforms are used by multiple partners, influencing the development of dozens of investigational medicines across oncology and immune-related diseases. Genmab plays a key role in advancing next-generation immunotherapies and expanding access to novel antibody-based treatments.